Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials".
Glenmark Pharmaceuticals Limited Press Release Feb 27 2026
Filed with NSE · · 2 pages · English
Watch Glenmark Pharmaceuticals' latest callGlenmark Pharmaceuticals (NSE:GLENMARK) Q1 2026 Earnings Call · Replay · Aug 3Read the transcript of Glenmark Pharmaceuticals (NSE:GLENMARK) Q1 2026 Earnings CallRelease
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Q3FY 2025-26
- Press Release Jan 30 2026
- Press Release Dec 23 2025
- Press Release Dec 16 2025
- Press Release Dec 11 2025
Later from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Mar 04 2026
- Glenmark Pharmaceuticals Limited Press Release Mar 16 2026
- Glenmark Pharmaceuticals Limited Press Release Mar 19 2026
- Glenmark Pharmaceuticals Limited Press Release Mar 21 2026
- Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals